Substance P (SP) immunoreactivity is detectable in the rat pituitary by RIA; however, immunollization has been difficult. We used a sensitive immunogold silverenhancement staining technique to cytochemically locate SP in the gland. SP-lmmunoreactive (SP-ir) cells were seen in anterior pituitary (AP), and occasional SP-ir fibers and terminals were seen in both AP and posterior pituitary. Coloalization studies showed the vast majority of SP-ir cells in the male AP to be also immunoreactive for growth hormone (GH). These GH/SP-ir cells represent -23% ofthe somatotroph population in the male. SP-ir cells did not colocalize with lactotrophs, gonadotrophs, or corticotrophs; however, rare thyroidstimulating hormone/SP-ir cells were found in the male AP. Comparisons of pituitaries from males and females revealed that females have 70% fewer SP-Ir cells and that only =%6% of the somatotrophs in the female express SP. This sexual dimorphism is diminished in 6-day ovariectomized rats because this treatment increases the GH/SP-ir cell population 3-fold. This result suggests that the previously reported estrogen-induced decrease in SP gene and peptide expression in the pituitary occurs, at least in part, in a subpopulation of somatotrophs. To test this hypothesis, distribution of SP-ir cells was examined in pituitaries from estrogen-and oil-treated ovariectomized rats. Estrogen reduced the percentage of somatotrophs with SP immunoreactivity by 70% compared with ovariectomized oiltreated controls, indicating that estrogen most likely regulates SP levels in the pituitary by acting on a subpopulation of somatotrophs to suppress SP expression. Estrogen does not appear to alter SP immunoreactiviy that is detected in the additional population of SP cells that colocalize with thyroidstimulating hormone. These SP-expressing thyrotrophs were seen 6-fold more frequently in the female than in the male pituitary, regardless of steroid status. These studies reveal that males have more total SP-ir cells in the AP than do females and that there is a sexually dimorphic pattern of SP distribution in the gland. Males have a higher percentage of SP-ir GH cells, whereas females have more SP-ir thyrotrophs than do males. Identification of independently regulated SP-ir somatotroph and thyrotroph populations provides a basis for investigating the roles of SP in autocrine or paracrine regulation of pituitary hormone secretion.
GH/SP-ir cells represent -23% ofthe somatotroph population in the male. SP-ir cells did not colocalize with lactotrophs, gonadotrophs, or corticotrophs; however, rare thyroidstimulating hormone/SP-ir cells were found in the male AP. Comparisons of pituitaries from males and females revealed that females have 70% fewer SP-Ir cells and that only =%6% of the somatotrophs in the female express SP. This sexual dimorphism is diminished in 6-day ovariectomized rats because this treatment increases the GH/SP-ir cell population 3-fold. This result suggests that the previously reported estrogen-induced decrease in SP gene and peptide expression in the pituitary occurs, at least in part, in a subpopulation of somatotrophs. To test this hypothesis, distribution of SP-ir cells was examined in pituitaries from estrogen-and oil-treated ovariectomized rats. Estrogen reduced the percentage of somatotrophs with SP immunoreactivity by 70% compared with ovariectomized oiltreated controls, indicating that estrogen most likely regulates SP levels in the pituitary by acting on a subpopulation of somatotrophs to suppress SP expression. Estrogen does not appear to alter SP immunoreactiviy that is detected in the additional population of SP cells that colocalize with thyroidstimulating hormone. These SP-expressing thyrotrophs were seen 6-fold more frequently in the female than in the male pituitary, regardless of steroid status. These studies reveal that males have more total SP-ir cells in the AP than do females and that there is a sexually dimorphic pattern of SP distribution in the gland. Males have a higher percentage of SP-ir GH cells, whereas females have more SP-ir thyrotrophs than do males. Identification of independently regulated SP-ir somatotroph and thyrotroph populations provides a basis for investigating the roles of SP in autocrine or paracrine regulation of pituitary hormone secretion.
Substance P (SP) immunoreactivity has been detected in the rat anterior pituitary (AP) by RIA (1) (2) (3) (4) and by immunohistochemistry in several species (5) (6) (7) (8) (9) (10) (11) (12) , and SP may act as a local modulator of pituitary function. Northern (RNA) blot and nuclease-protection analyses of RNA isolated from rat APs have revealed the presence of SP-encoding mRNAs in the gland (4, 13, 14) , indicating that cells within the AP synthesize SP. Furthermore, SP content in the AP is regulated by gonadal steroids: androgens increase and estrogen decreases pituitary SP levels (2-4), resulting in a sexual dimorphism, such that males have a higher SP content in the AP than do females (1-3). We recently showed that this differential gonadal steroid regulation of SP occurs directly by altering expression of SP mRNAs in the pituitary (4). These effects, along with evidence demonstrating that thyroid status can regulate SP expression in the AP (13) (14) (15) (16) (17) , suggest that SP is a hormonally regulated link in the regulation of pituitary secretion.
SP has been shown to alter either basal or stimulated release of all classic pituitary hormones in a variety of in vivo (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) and in vitro (21, 22, 24, 25, 28, 29) studies. Enhancement of prolactin (PRL) secretion is perhaps the best documented of the SP effects on pituitary function. This effect may be mediated locally (18, 19, 22, 27) but could occur through central hypothalamic SP systems (20, 22, 23, 27) .
To understand the functional significance of the SP synthesized within the AP, it is imperative to define which pituitary cell type(s) express and potentially secrete SP. In guinea pigs and humans SP immunoreactivity is present in thyrotrophs (5, 12) , and SP/thyroid-stimulating hormone (TSH) colocalization might be expected in the rat in light of evidence demonstrating that thyroid hormones can regulate pituitary SP expression (13) (14) (15) (16) (17) vehicle (n = 2 per treatment) daily for 6 days after surgery. These rats were perfused 24 hr after treatments ceased. Other OX rats (n = 2) were left untreated for 6 days before perfusion.
Immunohistochemistry. Rats were anesthetized with an overdose of sodium pentobarbital and perfused through the heart with 100 ml of isotonic saline followed by 150-200 ml of cold Bouins' fixative. Pituitaries were removed and postfixed for (12, 30) , subsequent incubations could be done with antisera raised in the same species. Therefore, rabbit anti-rat j8-TSH (S-5), rabbit antirat 8-luteinizing hormone (S-10), rabbit anti-rat p-follicle stimulating hormone (S-11), rabbit anti-rat PRL (S-9), and rabbit anti-human adrenocorticotropin (IC-1) were detected with either a Texas Red isothiocyanate (TRITC)-labeled goat anti-rabbit secondary serum (Sigma) or, for quadruplelabeling studies, a 7-amino-4-methylcoumarin-3-acetic acid (AMCA)-conjugated donkey anti-rabbit secondary serum (The Jackson Laboratory). Monkey anti-rat GH (S-5) antiserum was detected with a fluorescein isothiocyanate (FITC)-labeled goat anti-monkey secondary serum (Cappel Laboratories). In quadruple-labeling studies, a mouse antiopioid antibody (34) labeled with a rhodamine isothiocyanate (RITC)-tagged goat anti-mouse secondary serum (The Jackson Laboratory) was used to identify the opioid-expressing corticotrophs. This monoclonal antibody (3-E7) recognizes the sequence Tyr-Gly-Gly-Phe (34) common to all opioid peptides, including 8-endorphin, and was from E. Weber (University of California, Irvine). Primary incubations were done overnight at 40C with antisera diluted in blocking buffer as follows: 1:1000 for anti-gonadotropin, -TSH, and -adrenocorticotropin; 1: 2000 for anti-PRL and -opioid; and 1: 10,000 for anti-GH. Sections were then washed in PBS for 15 min, and secondary incubations were done in dilutions of 1:500 (TRITC, RITC, FITC) or 1:320 (AMCA) for 1 hr at room temperature, washed in PBS, and coverslipped with 50% (vol/vol) glycerol in PBS. Some slides were lightly counterstained with hematoxylin. Specificity of the antisera that colocalized with SP, anti-TSH, and anti-GH, was confirmed when staining was blocked by preincubating the antisera with 10 AM of the appropriate hormone, and when no staining was apparent by using normal rabbit or normal monkey sera.
However, blocking with 100 AM SP did not diminish staining with either of these antisera.
Quantitation was done by counting SP-positive cells in random fields of the AP at x500 magnification with a Zeiss microscope. A minimum of 10 random fields from two or more pituitaries from each group of animals was examined. Cell counts were averaged across fields, and the data are expressed as the mean percentage of SP-ir cells of either the somatotroph or thyrotroph populations ± SEM.
RESULTS
Immunogold silver-enhancement staining revealed a number of randomly distributed SP-ir cells in the male AP not detectable when the SP antiserum was incubated with 1 AuM SP or when normal rabbit serum was used ( Fig. 1 A and B) . Furthermore, we also observed SP-ir fibers and terminals in the AP and in the posterior pituitary (data not shown), which have been described in rat, monkey, and human (7) (8) (9) (10) (11) (12) Colocalization studies showed that most SP-ir cells within the male AP were double-labeled with GH antiserum (Fig. 1  D, E, and F) . This SP-ir cell population represents -23% of the somatotroph population in the male AP (Fig. 2) . Nearly all (98%) of the SP-ir cells in the male AP contained GH immunoreactivity and did not appear to colocalize with any of the other pituitary hormones, except for rare SP-ir cells containing TSH immunoreactivity (Fig. 2) . The SP cells make up =12% of the total AP cell population in the male, as determined by cell counts of hematoxylin-counterstained SP-ir fields.
Immunohistochemical analysis of APs from random cycling females revealed almost 4-fold fewer SP-ir cells compared with the male AP (Fig. 1C) . As in the male, many SP-ir cells in the female colocalize with GH ( Fig. 1 G, H, and I ), and these amounted to =75% of the SP-ir cells in the AP. These cells represent =6% of the somatotroph population (Fig. 2) . The remaining population of SP-ir cells (25%) colocalized with TSH ( Fig. 1 G, H, and I) , representing -8% of the thyrotrophs in the female (Fig. 2) . The SP-ir cell population in the female represents =3% of the total AP cell population.
Because there is a sexual dimorphism in SP content in the pituitary-in part due to estrogen suppressing SP expression in the female AP (2-4) and because females have 75% fewer somatotrophs with SP immunoreactivity than do males (Fig.  2) , it seemed that estrogen acts on a subpopulation of somatotrophs to down-regulate SP content. To test this Cell Biology: Brown et al. hypothesis, we performed SP immunohistochemistry on glands isolated from estrogen-and oil-treated OX rats. There were -3-to 4-fold more SP-ir cells in APs isolated from oil-treated OX rats compared to those from estrogen-treated OX rats or from normal cycling females (data not shown). There were no obvious differences between SP-ir cells in random cycling females and estrogen-stimulated OX rats.
Most of these SP-ir cells in APs of oil-treated OX rats colocalize with GH, representing an increase in the SPexpressing somatotroph population to almost 20%6 of all somatotrophs (Fig. 3) . There was no apparent effect of OX or estrogen replacement on the SP-ir thyrotroph population (Fig. 3) . The quantitative analysis here, however, is based on the presence or absence of immunoreactivity and does not attempt to distinguish between relative amounts of immunoreactivity. Consequently, estrogen-induced alterations in the amounts of SP immunoreactivity within thyrotrophs would not be detected in this analysis. Furthermore, it is possible that OX increased the number of SP-ir thyrotrophs but that levels ofSP expression were below sensitivity ofthe immunogold staining technique. DISCUSSION SP is present in nerve fibers and cell bodies in the posterior pituitary and in the AP of several species (5) (6) (7) (8) (9) (10) (11) (12) . Because SP may act directly at the level of the AP to induce PRL secretion (18, 19, 22, 27) (12) that SP does not colocalize with GH, and in guinea pig (5) and human (12) AP SP immunoreactivity is detected in TSH cells. Moreover, one study reported the presence of SP immunoreactivity in lactotrophs and gonadotrophs in rat (6) .
However, these investigators based pituitary cell type identification on ultrastructural evidence ofgranule size, whereas the present study used the more specific criterion of immunohistochemical localization of pituitary hormones. Furthermore, we have seen similar SP/GH colocalization using a different SP antiserum, R-140 (32, 33) , as well as a goat anti-human GH serum that crossreacts with rat GH (data not shown), and all criteria for antisera specificity were fulfilled by antigen-blocking controls.
Multiple-labeling studies revealed a rare SP-ir mammosomatotroph in the male AP (i.e., a cell triple-labeled with SP, GH, and PRL antisera). Such cells, believed to be progenitors of mature lactotrophs and somatotrophs (35), were not usually SP-ir. In fact, such expression would suggest that these rare cells were in the process of differentiating into somatotrophs, the cell type displaying most SP immunoreactivity. SP-expressing thyrotrophs in the female pituitary were much more common than in the male. Males had an occasional SP/TSH dual-positive cell, which probably represents the 2% of nonsomatotrophic SP cells in male AP. But such cells were never present to the degree seen in female pituitary, even when lower SP antiserum dilutions were used (1: 1000). The sex difference in SP/TSH distribution might reflect a sexual dimorphism in thyroid status because thyroid hormones can regulate SP expression in the pituitary (13) (14) (15) (16) (17) .
The 4-fold difference in the SP-expressing somatotroph population between males and females corresponds well to the sex difference reported (2, 3) by RIA in AP SP contentmales having 4-to 6-fold more pituitary SP than females. Because estrogen is, at least in part, responsible for the sexual dimorphism in SP content (2-4), we hypothesized that estrogen acts on a subpopulation of somatotrophs in the female pituitary to down-regulate SP expression. There is precedence for estrogen regulating somatotroph function. Estrogen stimulates GH secretion from the pituitary (36, 37) , and somatotrophs have been shown to bind [3H]estradiol in females in an ovarian-dependent fashion (38) . Furthermore, in the present study OX caused a 4-fold increase in the SP-expressing somatotroph population over the percentage seen in cycling females and in OX estrogen-stimulated rats. Therefore, the estrogen effects reported (2-4) on pituitary SP content and SP mRNA expression probably occur directly on a subpopulation of somatotrophs to suppress SP synthesis. Though androgen effects on SP distribution in the pituitary were not examined, the increases in SP immunoreactivity due to androgen stimulation reported (1-4) could occur in the somatotroph population because GH cells represent most SP-ir cells in the male pituitary.
Although the SP immunoreactivity described may be partly due to uptake of SP supplied either from pituitary sources or via the portal circulation, it is highly unlikely that all SP immunoreactivity seen in somatotrophs represents only uptake. SP mRNA is expressed within the AP (4, 13, 14) , so those cells synthesizing it should display some SP immunoreactivity. Furthermore, pituitary SP mRNA is downregulated by estrogen (4), causing decreased SP content in the gland (2-4) similar in magnitude (-50%) to the estrogeninduced suppression of somatotroph SP immunoreactivity observed in the present studies (-70%). Therefore, the estrogen-regulated SP immunoreactivity seen in somatotrophs probably represents SP expressed de novo in those cells.
The SP immunoreactivity detected in thyrotrophs in females may also represent SP expression in those cells.
Pituitary SP immunoreactivity in other species is contained in Cell Biology: Brown et al.
thyrotrophs (5, 12) , and thyroid hormones down-regulate SP mRNA expression in the rat pituitary (13, 14) . But thyroid status may affect pituitary cell types other than thyrotrophs. For instance, thyroid hormone replacement can reverse thyroidectomy-induced decreases in [3HJestradiol binding in the AP (38) , and decreases in [3H]estradiol binding in the hypothyroid state occur not only in thyrotrophs but in somatotrophs as well (39) . This fact indicates that thyroid hormones may up-regulate estrogen receptors in the somatotroph population, as has been demonstrated also in liver and kidney (40, 41) . This mechanism would provide one way by which thyroid hormones could decrease pituitary SP levels-i.e., by increasing the amount and/or availability of estrogen receptors in somatotrophs, so that more estradiol can inhibit SP mRNA expression.
The immunohistochemical evidence reported here shows that most SP immunoreactivity in the rat pituitary is associated with a subpopulation of somatotrophs that responds to estrogen by suppressing SP expression in the female pituitary. This result indicates that the GH-secreting cells in the pituitary use this steroid-regulated peptide perhaps as a local effector of pituitary function. SP may act in a paracrine fashion-that is, on cells different from the somatotrophs and thyrotrophs that presumably secrete it. For instance, it could act on lactotrophs because SP may locally induce PRL secretion (18, 19, 22, 27) . On the other hand, perhaps SP serves an autocrine role, acting on the same cell types that synthesis and secrete it, and, in fact, effects of SP on GH and TSH secretion have been documented (18, 19, 24, 28) . Vasoactive intestinal peptide has been shown to have such an autocrine function, being secreted from and acting on lactotrophs to induce PRL secretion (42) . Identification of the cell type(s) that bind and presumably respond to SP will distinguish between these possibilities and help determine the pituitary hormonal system(s) that communicate by means of SP.
